Selected research
Industry Research
Latanoprost for Chronic Angle Closure Glaucoma Industry Research Report 2026
Market perspective
The global Latanoprost for Chronic Angle Closure Glaucoma market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Latanoprost for Chronic Angle Closure Glaucoma is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Latanoprost for Chronic Angle Closure Glaucoma is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Latanoprost for Chronic Angle Closure Glaucoma is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Latanoprost for Chronic Angle Closure Glaucoma include CR Zizhu, Novartis, Mylan, China Medical System Holdings, Pfizer, Jiangsu Hengrui Pharmaceuticals, Teva, Taj Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Latanoprost for Chronic Angle Closure Glaucoma market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Latanoprost for Chronic Angle Closure Glaucoma Market by Company
CR Zizhu
Novartis
Mylan
China Medical System Holdings
Pfizer
Jiangsu Hengrui Pharmaceuticals
Teva
Taj Pharma
Apotex
Latanoprost for Chronic Angle Closure Glaucoma Segment by Type
Brand Drug
Generic Drug
Latanoprost for Chronic Angle Closure Glaucoma Segment by Application
Male Patients
Female Patients
Latanoprost for Chronic Angle Closure Glaucoma Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latanoprost for Chronic Angle Closure Glaucoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Latanoprost for Chronic Angle Closure Glaucoma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latanoprost for Chronic Angle Closure Glaucoma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Latanoprost for Chronic Angle Closure Glaucoma manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Latanoprost for Chronic Angle Closure Glaucoma by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Latanoprost for Chronic Angle Closure Glaucoma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Brand Drug
- Generic Drug
Applications
- Male Patients
- Female Patients
Companies covered
- CR Zizhu
- Novartis
- Mylan
- China Medical System Holdings
- Pfizer
- Jiangsu Hengrui Pharmaceuticals
- Teva
- Taj Pharma
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Market Size (2021-2032)
- 2.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales (2021-2032)
- 2.2.3 Global Latanoprost for Chronic Angle Closure Glaucoma Market Average Price (2021-2032)
- 2.3 Latanoprost for Chronic Angle Closure Glaucoma by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Brand Drug
- 2.3.3 Generic Drug
- 2.4 Latanoprost for Chronic Angle Closure Glaucoma by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Male Patients
- 2.4.3 Female Patients
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Latanoprost for Chronic Angle Closure Glaucoma Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue of Manufacturers (2021-2026)
- 3.4 Global Latanoprost for Chronic Angle Closure Glaucoma Average Price by Manufacturers (2021-2026)
- 3.5 Global Latanoprost for Chronic Angle Closure Glaucoma Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Latanoprost for Chronic Angle Closure Glaucoma, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Latanoprost for Chronic Angle Closure Glaucoma, Product Type & Application
- 3.8 Global Manufacturers of Latanoprost for Chronic Angle Closure Glaucoma, Established Date
- 3.9 Global Latanoprost for Chronic Angle Closure Glaucoma Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CR Zizhu
- 4.1.1 CR Zizhu Company Information
- 4.1.2 CR Zizhu Business Overview
- 4.1.3 CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.1.5 CR Zizhu Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 China Medical System Holdings
- 4.4.1 China Medical System Holdings Company Information
- 4.4.2 China Medical System Holdings Business Overview
- 4.4.3 China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.4.5 China Medical System Holdings Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Jiangsu Hengrui Pharmaceuticals
- 4.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.6.3 Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.7 Teva
- 4.7.1 Teva Company Information
- 4.7.2 Teva Business Overview
- 4.7.3 Teva Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Teva Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.7.5 Teva Recent Developments
- 4.8 Taj Pharma
- 4.8.1 Taj Pharma Company Information
- 4.8.2 Taj Pharma Business Overview
- 4.8.3 Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.8.5 Taj Pharma Recent Developments
- 4.9 Apotex
- 4.9.1 Apotex Company Information
- 4.9.2 Apotex Business Overview
- 4.9.3 Apotex Latanoprost for Chronic Angle Closure Glaucoma Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Apotex Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
- 4.9.5 Apotex Recent Developments
5 Global Latanoprost for Chronic Angle Closure Glaucoma Market Scenario by Region
- 5.1 Global Latanoprost for Chronic Angle Closure Glaucoma Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region: 2021-2032
- 5.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region: 2021-2026
- 5.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region: 2027-2032
- 5.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region: 2021-2032
- 5.3.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region: 2021-2026
- 5.3.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region: 2027-2032
- 5.4 North America Latanoprost for Chronic Angle Closure Glaucoma Market Facts & Figures by Country
- 5.4.1 North America Latanoprost for Chronic Angle Closure Glaucoma Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
- 5.4.3 North America Latanoprost for Chronic Angle Closure Glaucoma Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Latanoprost for Chronic Angle Closure Glaucoma Market Facts & Figures by Country
- 5.5.1 Europe Latanoprost for Chronic Angle Closure Glaucoma Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
- 5.5.3 Europe Latanoprost for Chronic Angle Closure Glaucoma Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Market Facts & Figures by Country
- 5.6.1 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Latanoprost for Chronic Angle Closure Glaucoma Market Facts & Figures by Country
- 5.7.1 South America Latanoprost for Chronic Angle Closure Glaucoma Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
- 5.7.3 South America Latanoprost for Chronic Angle Closure Glaucoma Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021-2032)
- 6.1.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Type (2021-2032)
- 6.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2021-2032)
- 6.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Type (2021-2032)
- 6.3 Global Latanoprost for Chronic Angle Closure Glaucoma Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021-2032)
- 7.1.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Application (2021-2032)
- 7.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2021-2032)
- 7.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Application (2021-2032)
- 7.3 Global Latanoprost for Chronic Angle Closure Glaucoma Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Latanoprost for Chronic Angle Closure Glaucoma Value Chain Analysis
- 8.1.1 Latanoprost for Chronic Angle Closure Glaucoma Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Latanoprost for Chronic Angle Closure Glaucoma Production Mode & Process
- 8.2 Latanoprost for Chronic Angle Closure Glaucoma Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Latanoprost for Chronic Angle Closure Glaucoma Distributors
- 8.2.3 Latanoprost for Chronic Angle Closure Glaucoma Customers
9 Global Latanoprost for Chronic Angle Closure Glaucoma Analyzing Market Dynamics
- 9.1 Latanoprost for Chronic Angle Closure Glaucoma Industry Trends
- 9.2 Latanoprost for Chronic Angle Closure Glaucoma Industry Drivers
- 9.3 Latanoprost for Chronic Angle Closure Glaucoma Industry Opportunities and Challenges
- 9.4 Latanoprost for Chronic Angle Closure Glaucoma Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst